Equities analysts forecast that Intra-Cellular Therapies Inc (NASDAQ:ITCI) will announce earnings of ($0.89) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Intra-Cellular Therapies’ earnings. The highest EPS estimate is ($0.84) and the lowest is ($0.94). Intra-Cellular Therapies posted earnings of ($0.65) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 36.9%. The company is scheduled to report its next earnings report on Thursday, May 2nd.

According to Zacks, analysts expect that Intra-Cellular Therapies will report full-year earnings of ($4.05) per share for the current fiscal year, with EPS estimates ranging from ($4.15) to ($4.00). For the next financial year, analysts forecast that the company will post earnings of ($3.05) per share, with EPS estimates ranging from ($3.75) to ($2.54). Zacks’ EPS averages are an average based on a survey of research firms that that provide coverage for Intra-Cellular Therapies.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its earnings results on Wednesday, February 27th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.91) by $0.16.

ITCI has been the subject of several research reports. Canaccord Genuity set a $31.00 price target on shares of Intra-Cellular Therapies and gave the company a “buy” rating in a research report on Wednesday, December 12th. BidaskClub upgraded shares of Intra-Cellular Therapies from a “strong sell” rating to a “sell” rating in a research report on Saturday, February 2nd. Zacks Investment Research lowered shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research report on Thursday, December 20th. ValuEngine upgraded shares of Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a research report on Friday, March 1st. Finally, Cantor Fitzgerald set a $32.00 price target on shares of Intra-Cellular Therapies and gave the company a “buy” rating in a research report on Tuesday, December 11th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. Intra-Cellular Therapies currently has a consensus rating of “Hold” and an average price target of $28.20.

Shares of NASDAQ ITCI traded up $0.08 during trading on Thursday, hitting $13.35. The stock had a trading volume of 292,958 shares, compared to its average volume of 329,643. Intra-Cellular Therapies has a 12 month low of $10.21 and a 12 month high of $25.82. The firm has a market cap of $724.83 million, a price-to-earnings ratio of -4.70 and a beta of 1.41.

In related news, CEO Sharon Mates sold 6,604 shares of the stock in a transaction dated Monday, January 7th. The shares were sold at an average price of $12.43, for a total transaction of $82,087.72. Following the completion of the transaction, the chief executive officer now owns 1,190,909 shares in the company, valued at $14,802,998.87. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Michael Halstead sold 21,458 shares of the stock in a transaction dated Friday, January 4th. The shares were sold at an average price of $11.46, for a total transaction of $245,908.68. Following the transaction, the executive vice president now owns 24,757 shares of the company’s stock, valued at approximately $283,715.22. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 113,209 shares of company stock valued at $1,301,080. 17.40% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Quantbot Technologies LP lifted its holdings in Intra-Cellular Therapies by 5,520.7% during the third quarter. Quantbot Technologies LP now owns 4,609 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 4,527 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in Intra-Cellular Therapies during the fourth quarter valued at about $142,000. Metropolitan Life Insurance Co. NY lifted its holdings in Intra-Cellular Therapies by 354.8% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 14,016 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 10,934 shares during the last quarter. Legal & General Group Plc lifted its holdings in Intra-Cellular Therapies by 9.4% during the fourth quarter. Legal & General Group Plc now owns 16,044 shares of the biopharmaceutical company’s stock valued at $183,000 after purchasing an additional 1,374 shares during the last quarter. Finally, Creative Planning purchased a new stake in Intra-Cellular Therapies during the fourth quarter valued at about $228,000. Institutional investors own 68.68% of the company’s stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders.

See Also: Understanding Price to Earnings Ratio (PE)

Get a free copy of the Zacks research report on Intra-Cellular Therapies (ITCI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.